Quidelortho Corp
A maker of medical diagnostic tests, QuidelOrtho supplies the rapid tests and lab analyzers doctors, hospitals, and blood banks use to spot illness and match blood types. It was born in 2022 when two companies merged: Quidel, founded in San Diego in 1979, and Ortho Clinical Diagnostics, whose roots reach back to 1939 as a Johnson & Johnson division that helped pioneer safe blood transfusions. Its Sofia analyzer—named for its fluorescent rapid-testing system—won a Good Design award for its small, user-friendly design.
Sold 12.46M
Granted 23.8K
Granted 36.3K
Granted 14.2K · Bought 10.0K
Granted 63.0K · Bought 40.1K
Granted 57.0K · Bought 8.1K
Granted 20.2K
Granted 26.8K · Sold 4.0K
Granted 42.0K
Granted 16.1K · Bought 1.0K
Granted 13.5K
Granted 16.6K
Granted 18.0K · Bought 750
Granted 27.4K
Granted 14.2K · Bought 370
Granted 8.5K
Granted 14.7K
Granted 19.0K
Granted 21.1K
Granted 10.3K · Bought 2.1K
Granted 9.4K
Granted 9.4K
Granted 5.0K
Granted 5.5K
Granted 1.5K
Granted 1.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| CG Subsidiary Holdings L.L.C. +8 co-filers10% owner · 104 transactions | — | 12.25Mas of Nov 2024 | — | — | 12.46M |
| Bryant Douglas CPresident & CEO, Director · 8 transactions | +2.6% | 549.4Kas of Feb 2024 | 23.8K | — | — |
| Buechler Kenneth FDirector · 11 transactions | +48.6% | 110.9K | 36.3K | — | — |
| Strobeck MatthewDirector · 4 transactions | +37.1% | 89.4K | 14.2K | 10.0K | — |
| Blaser Brian J.President and CEO · 9 transactions | — | 86.0K | 63.0K | 40.1K | — |
| Busky Joseph M.Chief Financial Officer · 16 transactions | — | 55.1K | 57.0K | 8.1K | — |
| Bujarski Robert JosephEVP & COO · 22 transactions | +23.2% | 45.0Kas of Oct 2024 | 20.2K | — | — |
| Widder Kenneth JDirector · 12 transactions | +100.9% | 44.8K | 26.8K | — | 4.0K |
| Hodges Michelle AChief Legal Officer · 26 transactions | — | 41.6K | 42.0K | — | — |
| Polan Mary Lake PH DDirector · 10 transactions | +56.3% | 37.6K | 16.1K | 1.0K | — |
| Kroll WernerSVP, Research & Development · 10 transactions | +24.7% | 37.0Kas of Jul 2024 | 13.5K | — | — |
| Michael Edward L.Director · 9 transactions | +129.5% | 29.4K | 16.6K | — | — |
| Rhoads Ann DDirector · 12 transactions | +417.3% | 23.3K | 18.0K | 750 | — |
| McLellan Philip D.Chief Operations Officer · 28 transactions | — | 22.5K | 27.4K | — | — |
| Wilkins Joseph D Jr.Director · 4 transactions | +349.5% | 18.7K | 14.2K | 370 | — |
| Iskra Michael S.EVP & CCO · 4 transactions | +64.5% | 17.9Kas of Jun 2024 | 8.5K | — | — |
| Dilsaver Evelyn SDirector · 5 transactions | +524% | 17.5K | 14.7K | — | — |
| Hodges Michelle A.Chief Legal Officer · 26 transactions | +253% | 16.7Kas of Dec 2024 | 19.0K | — | — |
| Siegrist Jonathan PhilipEVP of R&D & CTO · 4 transactions | — | 13.4K | 21.1K | — | — |
| Busky Joseph MChief Financial Officer · 5 transactions | — | 11.9Kas of Jun 2024 | 10.3K | 2.1K | — |
| Chiminski John RDirector · 2 transactions | — | 9.4K | 9.4K | — | — |
| Huennekens R ScottDirector · 2 transactions | — | 9.4K | 9.4K | — | — |
| Hanson Bryan MichaelEVP Global Port. Mgmt & Mkting · 4 transactions | — | 4.1K | 5.0K | — | — |
| Bowman Ronald LeeChief Human Resources Officer · 4 transactions | — | 3.4K | 5.5K | — | — |
| Brandy LouiseSVP, Chief Information Officer · 3 transactions | +146.3% | 2.7Kas of Apr 2024 | 1.5K | — | — |
| Prutow JamesDirector · 1 transaction | — | 1.5Kas of May 2024 | 1.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -12.40M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.